US EditionPublished • loading... • Updated
Merck in Talks to Buy Biotech Revolution in up to $32 Billion Deal, FT Reports
Merck aims to strengthen its oncology pipeline with Revolution Medicines’ RAS inhibitor drugs, addressing upcoming patent expirations on key cancer treatments.
- Thursday, Merck & Co. reportedly entered talks to acquire Revolution Medicines Inc. in a $28–$32 billion deal, but neither company immediately commented and talks could be weeks away.
- With Keytruda's protection ending in 2028, Merck & Co. has been acquiring assets like $9.2 billion and $10 billion targets, and earlier this year Revolution raised $2 billion via Royalty Pharma, people familiar with the matter say.
- Market reaction was swift: chatter first reported by the Financial Times sparked a 16% pre-market jump lifting Revolution's valuation above $24 billion, then shares rose 15.14% overnight to $123.65, while AbbVie Inc. was linked to talks on Thursday before denying involvement.
- If the deal closes, it would be the largest biotech transaction since Pfizer Inc.'s $43 billion Seagen acquisition and secure Revolution's daraxonrasib pipeline for PDAC and NSCLC.
- Near term, Revolution's clinical calendar shows RMC-5127, a RAS G12V-selective inhibitor, is due to start human testing later this quarter and data in previously treated PDAC are expected this year.
Insights by Ground AI
12 Articles
12 Articles
Merck in Talks to Acquire Revolution Medicines in USD 28-32 Billion Oncology Deal
New Delhi: Merck is in talks to buy cancer drug developer Revolution Medicines in a USD 28 billion to USD 32 billion deal, the Financial Times reported on Thursday, citing a person familiar with the...
·New Delhi, India
Read Full Article
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight - AbbVie (NYSE:ABBV), Cidara Therapeutics (NASDAQ:CDTX)
Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion.
·New York, United States
Read Full Article
Coverage Details
Total News Sources12
Leaning Left1Leaning Right1Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 17%
C 67%
R 16%
Factuality
To view factuality data please Upgrade to Premium
